Savara Inc. (SVRA) |
| 5.21 0.07 (1.36%) 05-27 16:00 |
| Open: | 5.15 |
| High: | 5.32 |
| Low: | 5.13 |
| Volume: | 823,178 |
| Market Cap: | 1,068(M) |
| PE Ratio: | -9.3 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 6.35 |
| Resistance 1: | 5.44 |
| Pivot price: | 5.10 |
| Support 1: | 4.98 |
| Support 2: | 4.70 |
| 52w High: | 7.005 |
| 52w Low: | 1.92 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Financials
| EPS | -0.560 |
| Book Value | 0.800 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.418 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -40.5 |
| Return on Equity (ttm) | -79.9 |
Company news
Wed, 27 May 2026
Rare lung disease biotech Savara heads to Jefferies investor conference - Stock Titan
Wed, 27 May 2026
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - Yahoo Finance
Wed, 27 May 2026
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA) - Seeking Alpha
Mon, 25 May 2026
New aPAP Phase 3 Data and Wider Losses Might Change The Case For Investing In Savara (SVRA) - simplywall.st
Fri, 22 May 2026
Savara Inc. (SVRA) Reports Q1 Financial Results - Yahoo Finance
Tue, 12 May 2026
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss - marketscreener.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
